Royalty Pharma Balance Sheet Health
Financial Health criteria checks 4/6
Royalty Pharma has a total shareholder equity of $9.8B and total debt of $7.6B, which brings its debt-to-equity ratio to 78%. Its total assets and total liabilities are $17.7B and $7.9B respectively. Royalty Pharma's EBIT is $960.2M making its interest coverage ratio 7.1. It has cash and short-term investments of $1.8B.
Key information
78.0%
Debt to equity ratio
US$7.60b
Debt
| Interest coverage ratio | 7.1x |
| Cash | US$1.80b |
| Equity | US$9.75b |
| Total liabilities | US$7.90b |
| Total assets | US$17.66b |
Recent financial health updates
Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28
Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Recent updates
Royalty Pharma (NASDAQ:RPRX) Has Affirmed Its Dividend Of $0.21
Oct 14Earnings Tell The Story For Royalty Pharma plc (NASDAQ:RPRX)
Oct 09Royalty Pharma (NASDAQ:RPRX) Takes On Some Risk With Its Use Of Debt
Aug 28Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
Aug 22Royalty Pharma: Busy Putting Capital To Work
Aug 11Royalty Pharma (NASDAQ:RPRX) Has Announced A Dividend Of $0.21
Jul 22Royalty Pharma plc (NASDAQ:RPRX) First-Quarter Results: Here's What Analysts Are Forecasting For This Year
May 12Royalty Pharma: Solid Start Of The Year, Buy Confirmed
May 11Royalty Pharma (NASDAQ:RPRX) Will Pay A Dividend Of $0.21
Apr 28Unpleasant Surprises Could Be In Store For Royalty Pharma plc's (NASDAQ:RPRX) Shares
Apr 25Is Royalty Pharma (NASDAQ:RPRX) Using Too Much Debt?
Apr 04Royalty Pharma's (NASDAQ:RPRX) Earnings Are Weaker Than They Seem
Feb 22Royalty Pharma: Solid Operational Performance
Feb 19Royalty Pharma (NASDAQ:RPRX) Will Pay A Larger Dividend Than Last Year At $0.21
Jan 31Royalty Pharma: One Of The Best Names In Pharmaceuticals
Jan 22Royalty Pharma plc's (NASDAQ:RPRX) Share Price Matching Investor Opinion
Dec 26Royalty Pharma's (NASDAQ:RPRX) Upcoming Dividend Will Be Larger Than Last Year's
May 12Royalty Pharma (NASDAQ:RPRX) Is Increasing Its Dividend To $0.20
Apr 20Royalty Pharma's (NASDAQ:RPRX) Dividend Will Be Increased To $0.20
Jan 16Royalty Pharma to co-fund development of schizophrenia drug with Merck
Oct 12Royalty Pharma: Strategic Royalty Interest Acquisition To Drive Significant Growth
Aug 18Financial Position Analysis
Short Term Liabilities: RPRX's short term assets ($2.6B) exceed its short term liabilities ($275.7M).
Long Term Liabilities: RPRX's short term assets ($2.6B) do not cover its long term liabilities ($7.6B).
Debt to Equity History and Analysis
Debt Level: RPRX's net debt to equity ratio (59.5%) is considered high.
Reducing Debt: RPRX's debt to equity ratio has reduced from 119.7% to 78% over the past 5 years.
Debt Coverage: RPRX's debt is well covered by operating cash flow (35.1%).
Interest Coverage: RPRX's interest payments on its debt are well covered by EBIT (7.1x coverage).